Cardiovascular Device Company Exceeds Patient Enrollment Goals Six Months Ahead of Schedule

Learn how a medical device company scaled its post-market trial for cardiovascular grafts and patches to meet new EU MDR requirements during the global pandemic.

With a flexible approach, IQVIA MedTech used its cardiovascular post-market clinical experience to exceed patient enrollment goals six months ahead of schedule.

Discover how IQVIA MedTech:

• Activated 31 sites across seven countries
• Helped the sponsor maintain EU MDR compliance on five legacy medical devices
• Leveraged its therapeutic area expertise to enroll and retain over 1,600 patients for a post-market cardiovascular trial that required long-term follow-up